"CRISPR's Future and Sickle Cell Research: Insights from Beam Therapeutics CEO"
Beam Therapeutics CEO John Evans discusses the company's plans to advance genetic medicine in sickle cell disease, including dosing the first sickle cell patient with its base-editing program and expecting initial human results in the second half of 2024. Evans, who has been leading Beam since 2017, also talks about the evolving landscape of CRISPR technology over the next two decades and the increasing competition in the field.
